Celgene files reply in support of injunction against Nimbus Therapeutics regarding psoriasis drug
MLex Summary: Celgene told a US judge that without an injunction against Nimbus Therapeutics it will suffer irreparable harm because the right to assign a Tyrosine-Kinase 2 inhibitor product that is...To view the full article, register now.
Already a subscriber? Click here to view full article